eslicarbazepine acetate has been researched along with Cognitive Dysfunction in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andermann, E; Ben-Menachem, E; Benbadis, SR; Biraben, A; Biton, V; Blum, D; CarreƱo, M; Cheng, H; Gama, H; Rocha, F; Shah, AK; Shneker, B; Trinka, E | 1 |
1 review(s) available for eslicarbazepine acetate and Cognitive Dysfunction
Article | Year |
---|---|
Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Clinical Trials, Phase III as Topic; Cognitive Dysfunction; Depression; Depressive Disorder; Dibenzazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Seizures; Treatment Outcome | 2018 |